P-ISSN 2575-3819
E-ISSN 2575-3827
Vol. 22, Issue 1, 2014January 01, 2014 EDT
Trade Secret Rising: Protecting Equivalency Test Research and Development Investments After Momenta v. Amphastar
Trade Secret Rising: Protecting Equivalency Test Research and Development Investments After Momenta v. Amphastar
Hannah-Alise Rogers,
patentHatch-Waxman ActFood and Drug AdministrationFDAsafe harbortrade secretFOIAAbbreviated New Drug ApplicationANDAUniform Trade Secrets ActUTSAdrug manufacturersgeneric manufacturerspharmaceuticalbioequivalency test; Momenta v. Amphastar
Articles in Vol. 22, Issue 1, 2014
Vol. 22, Issue 1, 2014
- Patent Office Contested Proceedings and the Duty of CandorLisa A. Dolak
- The Enforcement Challenges for Tattoo CopyrightsYolanda M. King
- The Viability of the $30 Casebook: Intellectual Property, Voluntary Payment, Open Distribution, and Author IncentivesLydia Pallas Loren
- Fault Lines in Trademark Default JudgmentsDavid S. Welkowitz
- Unauthorized Digital Sampling in the Changing Music LandscapeRyan Lloyd
- To Speak, Perchance to Have a Dream: The Malicious Author and Orator Estate as a Critique of the Digital Millennium Copyright Act's Subversion of the First Amendment in the Era of Notice and TakedownMichael Bradford Patterson
- Trade Secret Rising: Protecting Equivalency Test Research and Development Investments After Momenta v. AmphastarHannah-Alise Rogers
- Finders Keepers, or Finders Weepers? A Proposed Answer to a Question Raised by Myriad GeneticsJingshi Shi
Hannah-Alise Rogers, Trade Secret Rising: Protecting Equivalency Test Research and Development Investments After Momenta v. Amphastar, 22 Ga J.L. & Tech. 209 (2014).